Related references
Note: Only part of the references are listed.Efficacy of ONO-5334, a cathepsin K inhibitor, on bone mass and strength in ovariectomized cynomolgus monkeys
H. Yamada et al.
BONE (2011)
Efficacy of ONO-5334, a cathepsin K inhibitor, on bone turnover and cortical geometry in ovariectomized cynomolgus monkeys
Y. Ochi et al.
BONE (2011)
Cathepsin K Inhibitors Prevent Bone Loss in Estrogen-Deficient Rabbits
Brenda L. Pennypacker et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Odanacatib in the Treatment of Postmenopausal Women With Low Bone Mineral Density: Three-Year Continued Therapy and Resolution of Effect
John A. Eisman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Safety and Efficacy of the Cathepsin K Inhibitor ONO-5334 in Postmenopausal Osteoporosis: The OCEAN Study
Richard Eastell et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Osteoporosis: now and the future
Tilman D. Rachner et al.
LANCET (2011)
Bone density, strength, and formation in adult cathepsin K (-/-) mice
B. Pennypacker et al.
BONE (2009)
Local communication on and within bone controls bone remodeling
Kim Henriksen et al.
BONE (2009)
Treatment with a Potent Cathepsin K Inhibitor Preserves Cortical and Trabecular Bone Mass in Ovariectomized Monkeys
G. B. Stroup et al.
CALCIFIED TISSUE INTERNATIONAL (2009)
Advances in osteoclast biology resulting from the study of osteopetrotic mutations
T. Segovia-Silvestre et al.
HUMAN GENETICS (2009)
TGF-β1-induced migration of bone mesenchymal stem cells couples bone resorption with formation
Yi Tang et al.
NATURE MEDICINE (2009)
Osteoclast-osteoblast communication
Koichi Matsuo et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2008)
Functions of RANKL/RANK/OPG in bone modeling and remodeling
Brendan F. Boyce et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2008)
Osteoclast lineage and function
H. Kalervo Vaananen et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2008)
Biochemical properties and regulation of cathepsin K activity
Fabien Lecaille et al.
BIOCHIMIE (2008)
The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K
Jacques Yves Gauthier et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts
Karen Fuller et al.
BONE (2008)
Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial
Paul D. Miller et al.
BONE (2008)
Eph-ephrin bidirectional signaling in physiology and disease
Elena B. Pasquale
CELL (2008)
Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension
Jacob A. Stakkestad et al.
CLINICAL RHEUMATOLOGY (2008)
Drug-induced morphea: Report of a case induced by balicatib and review of the literature
Anna Peroni et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2008)
Cathepsin K inhibitors: A novel target for osteoporosis therapy
S. A. Stoch et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
High bone mineral density in pycnodysostotic patients with a novel mutation in the propeptide of cathepsin K
A. F. Schilling et al.
OSTEOPOROSIS INTERNATIONAL (2007)
Are nonresorbing osteoclasts sources of bone anabolic activity?
Morten A. Karsdal et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2007)
Effects of continuing or stopping alendronate after 5 years of treatment - The Fracture Intervention Trial long-term extension (FLEX): A randomized trial
Dennis M. Black et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis
Chen Zhao et al.
CELL METABOLISM (2006)
Mice lacking cathepsin K maintain bone remodeling but develop bone fragility despite high bone mass
Chao Yang Li et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2006)
Structure activity relationships of 5-, 6-, and 7-methyl -substituted azepan-3-one cathepsin K inhibitors
DS Yamashita et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Relation between age, femoral neck cortical stability, and hip fracture risk
PM Mayhew et al.
LANCET (2005)
The role of cathepsins in osteoporosis and arthritis:: Rationale for the design of new therapeutics
Y Yasuda et al.
ADVANCED DRUG DELIVERY REVIEWS (2005)
Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers
JC Gallagher et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2002)
Epidemiology and outcomes of osteoporotic fractures
SR Cummings et al.
LANCET (2002)
Accelerated turnover of metaphyseal trabecular bone in mice overexpressing cathepsin K
R Kiviranta et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2001)
Share Paper
